BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/19/2014 2:49:00 PM | Browse: 1132 | Download: 1349
 |
Received |
|
2014-06-11 08:13 |
 |
Peer-Review Started |
|
2014-06-11 16:53 |
 |
To Make the First Decision |
|
2014-07-10 17:21 |
 |
Return for Revision |
|
2014-07-11 16:41 |
 |
Revised |
|
2014-07-16 03:03 |
 |
Second Decision |
|
2014-09-10 13:32 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-09-10 13:56 |
 |
Articles in Press |
|
2014-09-10 13:56 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2014-11-06 08:25 |
 |
Publish the Manuscript Online |
|
2014-11-19 14:49 |
Category |
Oncology |
Manuscript Type |
Review |
Article Title |
Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status
|
Manuscript Source |
Invited Manuscript |
All Author List |
Antonia Digklia and Ioannis A Voutsadakis |
Funding Agency and Grant Number |
|
Corresponding Author |
Ioannis A Voutsadakis, MD, PhD, Division of Medical Oncology, Department of Internal Medicine, Sault Area Hospital, Sault Sainte Marie, Ontario, Canada and Division of Clinical Sciences, Northern Ontario School of Medicine, 750 Great Northern Road, Sault Ste Marie, ON P6B 0A8, Canada. ivoutsadakis@yahoo.com or |
Key Words |
Metronomic chemotherapy; Vascular endothelial growth factor; Angiogenesis; Bevacizumab; Vascular endothelial growth factor receptor |
Core Tip |
Metronomic chemotherapy has the potential to reduce the toxicity of chemotherapy administered with conventional schedules. In addition, understanding of the importance of angiogenesis in the mechanism of action of metronomic schedules provides a rational to combine this type of administration with targeted agents against the vascular endothelial growth factor signaling pathway. |
Publish Date |
2014-11-19 14:49 |
Citation |
Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med 2014; 4(4): 58-67 |
URL |
http://www.wjgnet.com/2220-315X/full/v4/i4/58.htm |
DOI |
http://dx.doi.org/10.5493/wjem.v4.i4.58 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345